1. Unstable angina pectoris and non-ST segment elevation myocardial infarction: subcutaneous injection 120U/kg (maximum dose 10000U), twice a day, continue for 5-8 days or until the condition is stable, and take aspirin at the same time; For those who plan to participate in the treatment but need delay, they can continue to use 5000U of daheparin sodium (female weight < 80kg, male < 70kg) or 7500U subcutaneous injection, twice a day.
2, to prevent the formation of deep vein thrombosis after surgery: 1 ~ 2 hours before the operation of 2500U subcutaneous injection, 12 hours after the operation of 2500U subcutaneous injection, then 2500U, once a day, continue for 5 ~ 10 days, until the patient can behave.
3. Avoid coagulation during hemodialysis and blood filtration: ① for patients with chronic renal failure without known bleeding risk, if hemodialysis or blood filtration does not exceed 4 hours, 5000U intravenously can be injected; If the duration is over 4 hours, 30 ~ 40U/kg intravenously was injected, followed by 10 ~ 15U/kg intravenously. ② For patients with high risk of bleeding in acute renal failure, intravenously inject 5 ~ 10U/kg. For patients undergoing hemodialysis with short treatment isolation, comprehensive monitoring against factor Xa should be conducted, and plasma concentration should be kept within the range of 0.2 to 0.4 anti-XA/mL.
4. Treatment of acute deep vein thrombosis: 200U/kg subcutaneous injection, once a day, daily total does not span 18000U. For patients with high bleeding risk, 100U/kg, twice a day. Oral warfarin treatment was started at the same time as the use of dapheparin, and the drug was discontinued when the INR reached 2.3 ~ 3.O (usually combined treatment for 5 days).
Heparins Manufacturer for Drug Interaction
Concomitant use of drugs that have an effect on hemostasis, such as thrombolytic drugs, acetylsalicylic acid, nonsteroidal anti-inflammatory drugs, vitamin K antagonists, and glucan may enhance the anticoagulant effect of heparin sodium.